Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALS 205

Drug Profile

ALS 205

Alternative Names: ALS-205; PMX-205

Latest Information Update: 12 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Queensland
  • Developer Alsonex Pharmaceuticals; University of Queensland
  • Class Antidementias; Cinnamates; Cyclic peptides; Indoles
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease
  • Discontinued Age-related macular degeneration; Autoimmune disorders; Inflammatory bowel diseases

Most Recent Events

  • 05 Dec 2019 Chemical structure information added
  • 26 Nov 2019 ALS 205 receives Orphan Drug status for Amyotrophic lateral sclerosis in European Union prior to November 2019 (Alsonex Pharmaceuticals pipeline, November 2019)
  • 26 Nov 2019 ALS 205 receives Orphan Drug status for Amyotrophic lateral sclerosis in USA prior to November 2019 (Alsonex Pharmaceuticals pipeline, November 2019)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top